P2‐106: Gilead sciences’ support of global efforts toward elimination of hepatitis C virus

首页> 外文期刊>Journal of viral hepatitis. >P2‐106: Gilead sciences’ support of global efforts toward elimination of hepatitis C virus

【24h】

P2‐106: Gilead sciences’ support of global efforts toward elimination of hepatitis C virus

机译：P2-106：Gilead Sciences对全球努力消除丙型肝炎病毒的支持

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of viral hepatitis.》 |2018年第s1期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词

相似文献

外文文献
中文文献
专利

1. P2‐106: Gilead sciences’ support of global efforts toward elimination of hepatitis C virus [J] . Journal of viral hepatitis. . 2018,第S1期

机译：P2-106：Gilead Sciences对全球努力消除丙型肝炎病毒的支持
2. The global burden of viral hepatitis: better estimates to guide hepatitis elimination efforts [J] . Wiktor Stefan Z., Hutin Yvan J-F The Lancet . 2016,第10049期

机译：病毒性肝炎的全球负担：更好的估计数，以指导消除肝炎的努力
3. The global burden of viral hepatitis: better estimates to guide hepatitis elimination efforts [J] . Wiktor Stefan Z., Hutin Yvan J-F The Lancet . 2016,第10049期

机译：病毒性肝炎的全球负担：更好的估计数，以指导消除肝炎的努力
4. The classification prognosis models of hepatitis b virus reactivation based on Bayes and support vector machine after feature extraction of genetic algorithm [C] . Guanpeng Wu, Yihui Liu, Shuai Wang, 2016 12th International Conference on Natural Computation, Fuzzy Systems and Knowledge Discovery . 2016

机译：遗传算法特征提取后基于贝叶斯和支持向量机的乙肝病毒再激活分类预测模型
5. The global decline in hepatitis A virus seroprevalence. [D] . Jacobsen, Kathryn Hustedt. 2005

机译：全球甲型肝炎病毒血清阳性率下降。
6. The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals [O] . Stephanie Popping, Debora Bade, Charles Boucher, 2019

机译：全球消除HBV和HCV感染的运动：国际病毒性肝炎消除会议和实现2030年消除目标的核心发展指标
7. Side effects of long-term oral antiviral therapy for hepatitis B Potential conflict of interest: Dr. Fontana is on the speaker's bureau or has received consulting fees from Gilead Sciences, Bristol-Meyers Squibb, and Roche Laboratories. [O] . Fontana, Robert J. 2009

机译：长期口服抗病毒治疗对乙型肝炎的副作用潜在的利益冲突：Fontana博士在发言人办公室或收到Gilead sciences，Bristol-meyers squibb和Roche Laboratories的咨询费。

P2‐106: Gilead sciences’ support of global efforts toward elimination of hepatitis C virus

著录项

相似文献

相关主题

期刊订阅